Biotechnology Pharmaceutical Market in US 2009-2013 report forecasts the Biotechnology Pharmaceutical market to grow at a CAGR of 7.7 percent, with Blood Modifiers accounting for the largest share of the market at 36.3 percent.
The major growth drivers include:
– Increasing demand for biotechnology drugs with enhanced efficiency, safety and popularity
– Revision of regulations and standards in favour of biotechnology drugs are encouraging more companies to invest in the field
– Increasing ageing population and the prevalence of chronic and age related illnesses is also driving the demand for biotechnology pharmaceuticals
However, the market is faced with some challenges which can inhibit the growth, such as the increasing healthcare expenditure in the US. Many biotechnology pharmaceutical companies are facing cost containment pressure. Lack of technical development and expertise is an issue as these companies need to employ highly skilled medical professionals.
For the purpose of this report, the Biotechnology Pharmaceutical market refers to drugs, medicines or vaccines developed through biotechnology such as recombinant DNA technology, combinatorial chemistry, gene therapy, and monoclonal antibodies. The report analyzes Biotechnology Pharmaceutical market’s recent performance and provides the US market revenue and growth rates from 2009 through to 2013. It also provides detailed market segmentation based on the type of disease the drugs are formulated to treat or based on therapeutic class. The report includes comprehensive analysis of various trends and changes taking place in the Biotechnology Pharmaceutical market in the US.
It also explains the factors influencing market growth and also inhibitors preventing their adoption. The report provides basic profiles of some of the leading vendors in the market
Table of Contents :
1. Introduction
2. Market Size and Forecast
3. Market Segmentation
4. Market Trends in Biotechnology Pharmaceutical in US
5. Market Drivers in Biotechnology Pharmaceutical in US
6. Market Challenges in Biotechnology Pharmaceutical in US
7. Vendors
8. Related Reports in this Series
For more information please contact :
http://www.aarkstore.com/reports/Biotechnology-Pharmaceutical-Market-in-US-2009-2013-61586.html
http://www.emarketreports.com
http://www.aarkwebsolutions.com/
From:Aarkstore Enterprise
Contact: Neel
Email:press@aarkstore.com
URL: www.aarkstore.com
More Reports
Anhui Anke Biotechnology (Group) Co., Ltd.-Detailed Product Pipeline
Avir Green Hills Biotechnology AG-Detailed Product Pipeline
Beijing Minhai Biotechnology Co., Ltd.-Detailed Product Pipeline
Bolder BioTechnology, Inc.-Detailed Product Pipeline
Cougar Biotechnology, Inc.-Detailed Product Pipeline
Cytos Biotechnology AG-Detailed Product Pipeline
Development Center for Biotechnology (DCB)-Detailed Product Pipeline
Genovate Biotechnology Co., Ltd. (GBL)-Detailed Product Pipeline
Shanghai United Cell Biotechnology Co., Ltd.-Detailed Product Pipeline
TaiGen Biotechnology Co., Ltd.-Detailed Product Pipeline
InNexus Biotechnology Inc.-Detailed Product Pipeline
JINIS Biotechnology Corporation-Detailed Product Pipeline
Medigen Biotechnology Corp.-Detailed Product Pipeline
Mogam Biotechnology Research Institute (MBRI)-Detailed Product Pipeline
Prana Biotechnology Limited-Detailed Product Pipeline
Champions Biotechnology, Inc.-Deals & Alliances Report
Tamir Biotechnology, Inc.-Deals & Alliances Report
Cytos Biotechnology AG-Deals & Alliances Report
InNexus Biotechnology Inc.-Deals & Alliances Report
Tamir Biotechnology, Inc.-Detailed Product Pipeline
Bolder BioTechnology, Inc.-Deals & Alliances Report
Angel Biotechnology-Deals & Alliances Report